Literature DB >> 11564665

Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).

H M Dodds, L P Rivory.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11564665      PMCID： PMC1572966          DOI： 10.1038/sj.bjp.0704282

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  7 in total

1.  Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)--a reexamination.

Authors:  P W Riddles; R L Blakeley; B Zerner
Journal:  Anal Biochem       Date:  1979-04-01       Impact factor: 3.365

2.  Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.

Authors:  C Blandizzi; B De Paolis ; R Colucci; G Lazzeri; F Baschiera; M Del Tacca
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).

Authors:  H M Dodds; L P Rivory
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

4.  The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.

Authors:  C L Morton; R M Wadkins; M K Danks; P M Potter
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

5.  Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.

Authors:  L P Rivory; J F Riou; M C Haaz; S Sable; M Vuilhorgne; A Commerçon; S M Pond; J Robert
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

6.  Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.

Authors:  Y Kawato; M Sekiguchi; K Akahane; Y Tsutomi; Y Hirota; H Kuga; W Suzuki; H Hakusui; K Sato
Journal:  J Pharm Pharmacol       Date:  1993-05       Impact factor: 3.765

7.  Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.

Authors:  L P Rivory; E Chatelut; P Canal; A Mathieu-Boué; J Robert
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.